OMNIQ Reports Third Quarter Financial Results

(Other OTC:OMQS),(OTC US:OMQS), SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) — OMNIQ Corp (OTCMTS: OMQS or “omniQ” or “the Company”) today announced its financial results for the third quarter 2025. The company reported $8.8 million in revenue and $3 million gross profit. The company continues to implement its cost-reduction strategy designed to strengthen profitability […]

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

(NASDAQ:BNTC), –Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301- -Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

(NASDAQ:ELDN), Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Strengthened balance sheet with $57.5 million financing to advance transplantation

Caring Brands Announces Closing of $4,000,000 Million Uplisting to Nasdaq

(NASDAQ:CABR), FORT PIERCE, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) — Caring Brands, Inc. (“Caring Brands” or the “Company”), a wellness consumer products company offering several over-the-counter (OTC) and cosmetic consumer products, today announced the closing of its underwritten U.S. public offering of 1,000,000 shares of common stock at a public offering price of $4.00 per

PIMCO Canada Corp. Announces Monthly Distributions for PIMCO Canada Exchange Traded Series

(TSX:PMIF),(TSX:PMIF-U),(TSX:IGCF),(TSX:PMNT),(TSX:PLDI), Not for distribution to United States newswire services or for dissemination in the United States TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — PIMCO Canada Corp. (“PIMCO Canada”) today announced the 2025 November cash distributions for the ETF series (“ETF Series”) of the PIMCO Canada mutual funds that distribute monthly (“Funds”). Unitholders of record of

Off The Hook YS Inc. Announces Closing of Initial Public Offering

(NYSE MKT:OTH), North Carolina, Nov. 14, 2025 (GLOBE NEWSWIRE) — Off The Hook YS Inc. (“Off The Hook” and the “Company”) (NYSE American: OTH), a premier yacht and boat wholesaler specializing in the buying and selling of yachts and boats, today announced the closing of its initial public offering of 3,750,000 shares of its common

Peyto Exploration & Development Corp. Confirms Monthly Dividend for December 15, 2025

(TSX:PEY), CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) — Peyto Exploration & Development Corp. (TSX: PEY) (“Peyto”) confirms that the monthly dividend with respect to November 2025 of $0.11 per common share is to be paid on December 15, 2025, for shareholders of record on November 30, 2025. Dividends paid by Peyto to Canadian residents

Rivalry Extends Closing Date for Non-Brokered Private Placement

(TSX-V:RVLY),(Boerse Frankfurt – Freiverkehr:9VK),(OTC US:RVLCF),(Other OTC:RVLCF), TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Rivalry Corp. (the “Company” or “Rivalry“) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), the leading sportsbook and iGaming operator for digital-first players, is extending the closing date for the final tranche of its non-brokered private placement (the “Private Placement“) previously announced on September

OMNIQ Reports Third Quarter Financial Results

OMNIQ Reports Third Quarter Financial Results Increased Profits in the Third Quarter 2025 GlobeNewswire November 14, 2025 SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) — OMNIQ Corp (OTCMTS: OMQS or “omniQ” or “the Company”) today announced its financial results for the third quarter 2025. The company reported $8.8 million in revenue and $3 million

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update GlobeNewswire November 14, 2025 –Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301- -Positive interim clinical study results from

Scroll to Top